Viewpoint

The European Medicines Agency’s thumbs-down for rare disease treatment Glybera flies in the face of Commission policy. It’s also against the wishes of the European Parliament, and the impetus DG Sanco is putting into Orphan Drugs. Worse still, it’s bad for patients and kills innovation. By Nuala Moran.

The existing EU rules on tech transfer agreements may be intellectually stimulating for competition lawyers and economists, but they often make little sense to businesses. The current review by the Commission should lead to simplification, say Bristows' Pat Treacy and Osman Zafar

The academic ‘father’ of open innovation is launching a European forum for it, in collaboration with the Science|Business Innovation Board. Henry Chesbrough discusses the European challenges.

Business schools can spur entrepreneurship through curriculum and culture. The key is to create an environment that encourages team learning and student initiative, allowing the entrepreneurial mindset to blossom, says INSEAD dean Dipak C. Jain

Over 600 researchers from all round Europe have contributed to a critical review of Horizon 2020. They say collaboration is needed across disciplines for the €80B research programme to deliver, writes EMRC Chair Liselotte Højgaard

The barriers between technology and industry must be knocked over to unleash European innovation, says Jean J. Botti of EADS

An Imperial College London study, for the Science|Business Innovation Board, looks at how professional investors pick winners – and draws some lessons for government funders

It’s often hard to quantify, but angel investing is a growing around the world. New data indicate this will be key to overcoming the growth challenges facing entrepreneurs, says the OECD's Karen Wilson

Alan Leshner, CEO of the American Association for the Advancement of Science, caused a stir at February’s EU ministerial conference in Copenhagen, with a hard-hitting speech on the state of US science. America's scientific eminence, 'is at risk' he said.

Hard-pressed healthcare systems can no longer pay premium prices for new drugs. The consequence will be less innovation in Europe says Andrew Witty, CEO of GlaxoSmithKline.